The DOI matches its Crossref record; 146 of the 146 references it cites were found in a registry or an index.
NANOBODIES®: A Review of Diagnostic and Therapeutic Applications
Open accessAbstract
NANOBODY® (a registered trademark of Ablynx N.V) molecules (Nbs), also referred to as single domain-based VHHs, are antibody fragments derived from heavy-chain only IgG antibodies found in the Camelidae family. Due to their small size, simple structure, high antigen binding affinity, and remarkable stability in extreme conditions, Nbs possess the potential to overcome several of the limitations of conventional monoclonal antibodies. For many years, Nbs have been of great interest in a wide variety of research fields, particularly in the diagnosis and treatment of diseases. This has culminated with the approval of the world’s first Nb based drug (Caplacizumab) in 2018 with others following, and more on the way. This review will provide an overview, with examples, of (i) the structure and advantages of Nbs compared to conventional monoclonal antibodies, (ii) methods used to generate and produce antigen-specific Nbs, (iii) applications for diagnostics, and (iv) ongoing clinical trials for Nb therapeutics as well as promising candidates for clinical development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Naturally occurring antibodies devoid of light chains
Hamers-Casterman, C., Atarhouch, T., Muyldermans, S., Robinson, G., Hammers, C., Songa, E. B., Bendahman, N., & Hammers, R. (1993) · Nature · doi:10.1038/363446a0 · Cited by 3,241 · cited 3×
“Remarkably, despite their truncated nature, these HCAbs displayed the ability to bind to a wide range of antigens, as shown through radioimmunoprecipitation and western blotting [1].”
BackgroundNanobodies: natural single-domain antibodies
Muyldermans, S. (2013) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-063011-092449 · Cited by 2,304
Berdeja, J. G., Madduri, D., Usmani, S. Z., Jakubowiak, A., Agha, M., Cohen, A. D., Stewart, A. K., Hari, P., Htut, M., Lesokhin, A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00933-8 · Cited by 1,756 · cited 1×
“It completed phase 1 clinical trials successfully and underwent further phase 2 trials [123,124].”
BackgroundKoczula, K. M., & Gallotta, A. (2016) · Essays in Biochemistry · doi:10.1042/ebc20150012 · Cited by 1,147
Diagnostics for the developing world
Mabey, D., Peeling, R. W., Ustianowski, A., & Perkins, M. D. (2004) · Nature Reviews Microbiology · doi:10.1038/nrmicro841 · Cited by 1,054
A general protocol for the generation of Nanobodies for structural biology
Pardon, E., Laeremans, T., Triest, S., Rasmussen, S. G. F., Wohlkönig, A., Ruf, A., Muyldermans, S., Hol, W. G. J., Kobilka, B. K., & Steyaert, J. (2014) · Nature Protocols · doi:10.1038/nprot.2014.039 · Cited by 790
Selection and identification of single domain antibody fragments from camel heavy‐chain antibodies
Arbabi Ghahroudi, M., Desmyter, A., Wyns, L., Hamers, R., & Muyldermans, S. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)01062-4 · Cited by 768
The therapeutic potential of nanobodies
Jovčevska, I., & Muyldermans, S. (2020) · BioDrugs · doi:10.1007/s40259-019-00392-z · Cited by 749
Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies
De Genst, E., Silence, K., Decanniere, K., Conrath, K., Loris, R., Kinne, J., Muyldermans, S., & Wyns, L. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505379103 · Cited by 676
Single‐domain antibody fragments with high conformational stability
Dumoulin, M., Conrath, K., Van Meirhaeghe, A., Meersman, F., Heremans, K., Frenken, L. G. J., Muyldermans, S., Wyns, L., & Matagne, A. (2002) · Protein Science · doi:10.1110/ps.34602 · Cited by 638
Vincke, C., Loris, R., Saerens, D., Martinez-Rodriguez, S., Muyldermans, S., & Conrath, K. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m806889200 · Cited by 572
Single domain camel antibodies: current status
Muyldermans, S. (2001) · Reviews in Molecular Biotechnology · doi:10.1016/s1389-0352(01)00021-6 · Cited by 552
Yeast surface display platform for rapid discovery of conformationally selective nanobodies
McMahon, C., Baier, A. S., Pascolutti, R., Wegrecki, M., Zheng, S., Ong, J. X., Erlandson, S. C., Hilger, D., Rasmussen, S. G. F., Ring, A. M., et al. (2018) · Nature Structural & Molecular Biology · doi:10.1038/s41594-018-0028-6 · Cited by 546
Camelid immunoglobulins and nanobody technology
Muyldermans, S., Baral, T. N., Retamozzo, V. C., De Baetselier, P., De Genst, E., Kinne, J., Leonhardt, H., Magez, S., Nguyen, V. K., Revets, H., et al. (2009) · Veterinary Immunology and Immunopathology · doi:10.1016/j.vetimm.2008.10.299 · Cited by 533
Self-citationKilling Mechanisms of Chimeric Antigen Receptor (CAR) T Cells
Benmebarek, M.-R., Karches, C. H., Cadilha, B. L., Lesch, S., Endres, S., & Kobold, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061283 · Cited by 531
Crystal structure of a camel single-domain VH antibody fragment in complex with lysozyme
Desmyter, A., Transue, T. R., Ghahroudi, M. A., Dao Thi, M.-H., Poortmans, F., Hamers, R., Muyldermans, S., & Wyns, L. (1996) · Nature Structural & Molecular Biology · doi:10.1038/nsb0996-803 · Cited by 522
Zhao, W.-H., Liu, J., Wang, B.-Y., Chen, Y.-X., Cao, X.-M., Yang, Y., Zhang, Y.-L., Wang, F.-X., Zhang, P.-Y., Lei, B., et al. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0681-6 · Cited by 518
Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2
Huo, J., Le Bas, A., Ruza, R. R., Duyvesteyn, H. M. E., Mikolajek, H., Malinauskas, T., Tan, T. K., Rijal, P., Dumoux, M., Ward, P. N., et al. (2020) · Nature Structural & Molecular Biology · doi:10.1038/s41594-020-0469-6 · Cited by 500
Muyldermans, S., Atarhouch, T., Saldanha, J., Barbosa, J. A. R. G., & Hamers, R. (1994) · "Protein Engineering, Design and Selection" · doi:10.1093/protein/7.9.1129 · Cited by 494
Phase I Study of 68Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma
Keyaerts, M., Xavier, C., Heemskerk, J., Devoogdt, N., Everaert, H., Ackaert, C., Vanhoeij, M., Duhoux, F. P., Gevaert, T., Simon, P., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.162024 · Cited by 429
Guo, K., Wustoni, S., Koklu, A., Díaz-Galicia, E., Moser, M., Hama, A., Alqahtani, A. A., Ahmad, A. N., Alhamlan, F. S., Shuaib, M., et al. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00734-9 · Cited by 410
Domain association in immunoglobulin molecules
Chothia, C., Novotný, J., Bruccoleri, R., & Karplus, M. (1985) · Journal of Molecular Biology · doi:10.1016/0022-2836(85)90137-8 · Cited by 395
Durable antitumor responses to CD47 blockade require adaptive immune stimulation
Sockolosky, J. T., Dougan, M., Ingram, J. R., Ho, C. C. M., Kauke, M. J., Almo, S. C., Ploegh, H. L., & Garcia, K. C. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1604268113 · Cited by 366
A guide to: generation and design of nanobodies
Muyldermans, S. (2021) · The FEBS Journal · doi:10.1111/febs.15515 · Cited by 352
Nanobody: outstanding features for diagnostic and therapeutic applications
Salvador, J.-P., Vilaplana, L., & Marco, M.-P. (2019) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-019-01633-4 · Cited by 350
Comparison of llama VH sequences from conventional and heavy chain antibodies
Vu, K. B., Ghahroudi, M. A., Wyns, L., & Muyldermans, S. (1997) · Molecular Immunology · doi:10.1016/s0161-5890(97)00146-6 · Cited by 343
Muyldermans, S. (2021) · Annual Review of Animal Biosciences · doi:10.1146/annurev-animal-021419-083831 · Cited by 338
Moutel, S., Bery, N., Bernard, V., Keller, L., Lemesre, E., de Marco, A., Ligat, L., Rain, J.-C., Favre, G., Olichon, A., et al. (2016) · eLife · doi:10.7554/elife.16228 · Cited by 324
Muyldermans, S., Cambillau, C., & Wyns, L. (2001) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(01)01790-x · Cited by 322
Coppieters, K., Dreier, T., Silence, K., Haard, H. D., Lauwereys, M., Casteels, P., Beirnaert, E., Jonckheere, H., Wiele, C. V. D., Staelens, L., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21827 · Cited by 303
Nguyen, V. K., Hamers, R., Wyns, L., & Muyldermans, S. (2000) · The EMBO Journal · doi:10.1093/emboj/19.5.921 · Cited by 299
Nanobodies: Next Generation of Cancer Diagnostics and Therapeutics
Yang, E. Y., & Shah, K. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01182 · Cited by 291
Caplacizumab: First Global Approval
Duggan, S. (2018) · Drugs · doi:10.1007/s40265-018-0989-0 · Cited by 245
Applications of Yeast Surface Display for Protein Engineering
Cherf, G. M., & Cochran, J. R. (2015) · Methods in Molecular Biology · doi:10.1007/978-1-4939-2748-7_8 · Cited by 237
Comparative analysis of nanobody sequence and structure data
Mitchell, L. S., & Colwell, L. J. (2018) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.25497 · Cited by 233
Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants
Xu, J., Xu, K., Jung, S., Conte, A., Lieberman, J., Muecksch, F., Lorenzi, J. C. C., Park, S., Schmidt, F., Wang, Z., et al. (2021) · Nature · doi:10.1038/s41586-021-03676-z · Cited by 232
Xavier, C., Vaneycken, I., D’huyvetter, M., Heemskerk, J., Keyaerts, M., Vincke, C., Devoogdt, N., Muyldermans, S., Lahoutte, T., & Caveliers, V. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.111021 · Cited by 230
Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade
Zhang, F., Wei, H., Wang, X., Bai, Y., Wang, P., Wu, J., Jiang, X., Wang, Y., Cai, H., Xu, T., et al. (2017) · Cell Discovery · doi:10.1038/celldisc.2017.4 · Cited by 226
Targeted Radionuclide Therapy with A 177Lu-labeled Anti-HER2 Nanobody
D'Huyvetter, M., Vincke, C., Xavier, C., Aerts, A., Impens, N., Baatout, S., De Raeve, H., Muyldermans, S., Caveliers, V., Devoogdt, N., et al. (2014) · Theranostics · doi:10.7150/thno.8156 · Cited by 225
Immunogenicity Risk Profile of Nanobodies
Ackaert, C., Smiejkowska, N., Xavier, C., Sterckx, Y. G. J., Denies, S., Stijlemans, B., Elkrim, Y., Devoogdt, N., Caveliers, V., Lahoutte, T., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.632687 · Cited by 219
Thermal Unfolding of a Llama Antibody Fragment: A Two-State Reversible Process
Pérez, J. M. J., Renisio, J. G., Prompers, J. J., van Platerink, C. J., Cambillau, C., Darbon, H., & Frenken, L. G. J. (2001) · Biochemistry · doi:10.1021/bi0009082 · Cited by 199
Hultberg, A., Temperton, N. J., Rosseels, V., Koenders, M., Gonzalez-Pajuelo, M., Schepens, B., Ibañez, L. I., Vanlandschoot, P., Schillemans, J., Saunders, M., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017665 · Cited by 195
Oliveira, S., van Dongen, G. A. M. S., Walsum, M. S.-V., Roovers, R. C., Stam, J. C., Mali, W., van Diest, P. J., & van Bergen en Henegouwen, P. M. P. (2012) · Molecular Imaging · doi:10.2310/7290.2011.00025 · Cited by 194
SPECT Imaging with 99mTc-Labeled EGFR-Specific Nanobody for In Vivo Monitoring of EGFR Expression
Huang, L., Gainkam, L. O. T., Caveliers, V., Vanhove, C., Keyaerts, M., De Baetselier, P., Bossuyt, A., Revets, H., & Lahoutte, T. (2008) · Molecular Imaging and Biology · doi:10.1007/s11307-008-0133-8 · Cited by 192
Single-domain antibodies as building blocks for novel therapeutics
SAERENS, D., GHASSABEH, G., & MUYLDERMANS, S. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.07.006 · Cited by 186
The structural basis of nanobody unfolding reversibility and thermoresistance
Kunz, P., Zinner, K., Mücke, N., Bartoschik, T., Muyldermans, S., & Hoheisel, J. D. (2018) · Scientific Reports · doi:10.1038/s41598-018-26338-z · Cited by 181
Vincke, C., Gutiérrez, C., Wernery, U., Devoogdt, N., Hassanzadeh-Ghassabeh, G., & Muyldermans, S. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-61779-974-7_8 · Cited by 180
Generation of synthetic nanobodies against delicate proteins
Zimmermann, I., Egloff, P., Hutter, C. A. J., Kuhn, B. T., Bräuer, P., Newstead, S., Dawson, R. J. P., Geertsma, E. R., & Seeger, M. A. (2020) · Nature Protocols · doi:10.1038/s41596-020-0304-x · Cited by 177
Immunogenicity and humanization of single‐domain antibodies
Rossotti, M. A., Bélanger, K., Henry, K. A., & Tanha, J. (2022) · The FEBS Journal · doi:10.1111/febs.15809 · Cited by 173
Structural basis of epitope recognition by heavy-chain camelid antibodies
Zavrtanik, U., Lukan, J., Loris, R., Lah, J., & Hadži, S. (2018) · Journal of Molecular Biology · doi:10.1016/j.jmb.2018.09.002 · Cited by 169
Experimental therapy of African trypanosomiasis with a nanobody-conjugated human trypanolytic factor
Baral, T. N., Magez, S., Stijlemans, B., Conrath, K., Vanhollebeke, B., Pays, E., Muyldermans, S., & De Baetselier, P. (2006) · Nature Medicine · doi:10.1038/nm1395 · Cited by 166
Self-citationX-Ray Crystallography of Antibodies
Padlan, E. A. (1996) · Advances in Protein Chemistry · doi:10.1016/s0065-3233(08)60488-x · Cited by 165
Functional heavy-chain antibodies in camelidae
Nguyen, V. K., Desmyter, A., & Muyldermans, S. (2001) · Advances in Immunology · doi:10.1016/s0065-2776(01)79006-2 · Cited by 165
Engineered Single-Domain Antibodies with High Protease Resistance and Thermal Stability
Hussack, G., Hirama, T., Ding, W., MacKenzie, R., & Tanha, J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028218 · Cited by 160
Jailkhani, N., Ingram, J. R., Rashidian, M., Rickelt, S., Tian, C., Mak, H. H., Jiang, Z.-G., Ploegh, H. L., & Hynes, R. O. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1817442116 · Cited by 158
Papp, K. A., Weinberg, M. A., Morris, A., & Reich, K. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00440-2 · Cited by 154
The crystal structure of a llama heavy chain variable domain
Spinelli, S., Frenken, L. A. M., Bourgeois, D., de Ron, L., Bos, W., Verrips, T. C., Anguille, C., Cambillau, C., & TEGONI, M. (1996) · Nature Structural & Molecular Biology · doi:10.1038/nsb0996-752 · Cited by 149
Zhao, W., Wang, B., Chen, L., Fu, W., Xu, J., Liu, J., Jin, S., Chen, Y., Cao, X.-M., Yang, Y., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01301-8 · Cited by 144
Muyldermans, S., & Lauwereys, M. (1999) · Journal of Molecular Recognition · Cited by 141
Analysis of nanobody paratopes reveals greater diversity than classical antibodies
Mitchell, L. S., & Colwell, L. J. (2018) · Protein Engineering Design and Selection · doi:10.1093/protein/gzy017 · Cited by 138
Nanobody: A Small Antibody with Big Implications for Tumor Therapeutic Strategy
Sun, S., Ding, Z., Yang, X., Zhao, X., Zhao, M., Gao, L., Chen, Q., Xie, S., Liu, A., Yin, S., et al. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s297631 · Cited by 138
Tanaka, T. U., Lobato, M. N., & Rabbitts, T. H. (2003) · Journal of Molecular Biology · doi:10.1016/s0022-2836(03)00836-2 · Cited by 128
A bispecific nanobody to provide full protection against lethal scorpion envenoming
Hmila, I., Saerens, D., Abderrazek, R. B., Vincke, C., Abidi, N., Benlasfar, Z., Govaert, J., Ayeb, M. E., Bouhaouala‐Zahar, B., & Muyldermans, S. (2010) · The FASEB Journal · doi:10.1096/fj.09-148213 · Cited by 125
Richard, G., Meyers, A. J., McLean, M. D., Arbabi‐Ghahroudi, M., MacKenzie, R., & Hall, J. C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069495 · Cited by 124
D’Huyvetter, M., Vos, J. D., Caveliers, V., Vaneycken, I., Heemskerk, J., Duhoux, F. P., Fontaine, C., Vanhoeij, M., Windhorst, A. D., van der Aa, F., et al. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.255679 · Cited by 124
Nguyen, V. K., HAMERS, R., Wyns, L., & Muyldermans, S. (1999) · Molecular Immunology · doi:10.1016/s0161-5890(99)00067-x · Cited by 123
Single-Domain Antibodies or Nanobodies: A Class of Next-Generation Antibodies
Khodabakhsh, F., Behdani, M., Rami, A., & Kazemi‐Lomedasht, F. (2018) · International Reviews of Immunology · doi:10.1080/08830185.2018.1526932 · Cited by 123
18F-nanobody for PET imaging of HER2 overexpressing tumors
Xavier, C., Blykers, A., Vaneycken, I., D’Huyvetter, M., Heemskerk, J. W. T., Lahoutte, T., Devoogdt, N., & Caveliers, V. (2016) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2016.01.002 · Cited by 120
Escherichia coli surface display for the selection of nanobodies
Salema, V. F., & Fernández, L. Á. (2017) · Microbial Biotechnology · doi:10.1111/1751-7915.12819 · Cited by 117
Huet, H. A., Growney, J. D., Johnson, J. A., Li, J., Bilic, S., Ostrom, L., Zafari, M. R., Kowal, C., Yang, G., Royo, A., et al. (2014) · mAbs · doi:10.4161/19420862.2014.975099 · Cited by 116
Albert, S., Arndt, C., Feldmann, A., Bergmann, R., Bachmann, D., Koristka, S., Ludwig, F., Ziller-Walter, P., Kegler, A., Gärtner, S., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1287246 · Cited by 116
An improved yeast surface display platform for the screening of nanobody immune libraries
Uchański, T., Zögg, T., Yin, J., Yuan, D., Wohlkönig, A., Fischer, B., Rosenbaum, D. M., Kobilka, B. K., Pardon, E., & Steyaert, J. (2019) · Scientific Reports · doi:10.1038/s41598-018-37212-3 · Cited by 114
Transportation of Single-Domain Antibodies through the Blood–Brain Barrier
Ruiz-López, E., & Schuhmacher, A. J. (2021) · Biomolecules · doi:10.3390/biom11081131 · Cited by 114
Nanobody-Facilitated Multiparametric PET/MRI Phenotyping of Atherosclerosis
Senders, M. L., Hernot, S., Carlucci, G., van de Voort, J. C., Fay, F., Calcagno, C., Tang, J., Alaarg, A., Zhao, Y., Ishino, S., et al. (2018) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2018.07.027 · Cited by 113
Decanniere, K., Muyldermans, S., & Wyns, L. (2000) · Journal of Molecular Biology · doi:10.1006/jmbi.2000.3839 · Cited by 110
Torres, J. E. P., Goossens, J., Ding, J., Li, Z., Lu, S., Vertommen, D., Naniima, P., Chen, R., Muyldermans, S., Sterckx, Y. G. ‐., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-26732-7 · Cited by 108
Self-citationKeam, S. J. (2022) · Drugs · doi:10.1007/s40265-022-01821-0 · Cited by 107
Koklu, A., Wustoni, S., Guo, K., Silva, R. K. S., Salvigni, L., Hama, A., Díaz‐Galicia, E., Moser, M., Marks, A., McCulloch, I. A., et al. (2022) · Advanced Materials · doi:10.1002/adma.202202972 · Cited by 101
Richards, D. A. (2018) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2018.10.005 · Cited by 96
Therapeutic stem cells expressing variants of EGFR-specific nanobodies have antitumor effects
van de Water, J. A. J. M., Onder, T. B., Agarwal, A. S., Wakimoto, H., Roovers, R. C., Zhu, Y., Kasmieh, R., Bhere, D., Henegouwen, P. M. P. V. B. E., & Shah, K. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1202832109 · Cited by 95
Jamnani, F. R., Rahbarizadeh, F., Shokrgozar, M. A., Mahboudi, F., Ahmadvand, D., Sharifzadeh, Z., Parhamifar, L., & Moghimi, S. M. (2013) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2013.09.029 · Cited by 93
Behdani, M., Zeinali, S., Karimipour, M., Khanahmad, H., Schoonooghe, S., Aslemarz, A., Seyed, N., Moazzami, R., Baniahmad, F., Habibi‐Anbouhi, M., et al. (2012) · New Biotechnology · doi:10.1016/j.nbt.2012.09.002 · Cited by 89
Generation of heavy-chain-only antibodies in mice
Janssens, R., Dekker, S., Hendriks, R. W., Panayotou, G., van Remoortere, A., San, J. K. A., Grosveld, F. G., & Drabek, D. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601108103 · Cited by 89
Identification and in vivo characterization of a brain-penetrating nanobody
Wouters, Y., Jaspers, T., Strooper, B. D., & Dewilde, M. (2020) · Fluids and Barriers of the CNS · doi:10.1186/s12987-020-00226-z · Cited by 89
Nanobody conjugated PLGA nanoparticles for active targeting of African Trypanosomiasis
Arias, J. L., Unciti-Broceta, J. D., Maceira, J., del Castillo, T., Hernández-Quero, J., Magez, S., Soriano, M., & García-Salcedo, J. A. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.11.002 · Cited by 88
Self-citationLiu, X., Tang, Z., Duan, Z., He, Z., Shu, M., Wang, X., Gee, S. J., Hammock, B. D., & Xu, Y. (2016) · Talanta · doi:10.1016/j.talanta.2016.11.039 · Cited by 86
Bobkov, V., Zarca, A. M., Hout, A. V., Arimont, M., Doijen, J., Bialkowska, M., Toffoli, E. C., Klarenbeek, A., van der Woning, B., van der Vliet, H. J., et al. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.10.014 · Cited by 83
Specific Cell Targeting Therapy Bypasses Drug Resistance Mechanisms in African Trypanosomiasis
Unciti-Broceta, J. D., Arias, J. L., Maceira, J., Soriano, M., Ortiz-González, M., Hernández‐Quero, J., Muñoz‐Torres, M., de Koning, H. P., Magez, S., & Garcia-Salcedo, J. A. (2015) · PLoS Pathogens · doi:10.1371/journal.ppat.1004942 · Cited by 79
Self-citationWoolven, B. P., Frenken, L. G. J., van der Logt, P., & NICHOLLS, P. J. (1999) · Immunogenetics · doi:10.1007/s002510050694 · Cited by 78
Ma, H., Zeng, W., Meng, X., Huang, X., Yang, Y., Zhao, D., Zhou, P., Wang, X., Zhao, C., Sun, Y. C., et al. (2021) · Journal of Virology · doi:10.1128/jvi.02438-20 · Cited by 76
Sarker, S. A., Jäkel, M., Sultana, S., Alam, N. H., Bardhan, P. K., Chisti, M. J., Salam, M. A., Theis, W., Hammarström, L. L. G., & Frenken, L. G. J. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.06.053 · Cited by 74
Nanobody-Based Probes for Subcellular Protein Identification and Visualization
de Beer, M. A., & Giepmans, B. N. G. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.573278 · Cited by 74
Selection of specific nanobodies to develop an immuno-assay detecting Staphylococcus aureus in milk
Hu, Y., Sun, Y., Gu, J., Yang, F., Wu, S., Zhang, C., Ji, X., Lv, H., Muyldermans, S., & Wang, S. (2021) · Food Chemistry · doi:10.1016/j.foodchem.2021.129481 · Cited by 74
Varasteh, Z., Mohanta, S. K., Li, Y., Armbruster, N. L., Braeuer, M., Nekolla, S. G., Habenicht, A. J. R., Sager, H. B., Raes, G., Weber, W., et al. (2019) · EJNMMI Research · doi:10.1186/s13550-019-0474-0 · Cited by 69
FDA approves second BCMA-targeted CAR-T cell therapy
Mullard, A. (2022) · Nature Reviews Drug Discovery · doi:10.1038/d41573-022-00048-8 · Cited by 68
Using microdialysis to analyse the passage of monovalent nanobodies through the blood–brain barrier
Caljon, G., Caveliers, V., Lahoutte, T., Stijlemans, B., Ghassabeh, G. H., Abbeele, J. V. D., Smolders, I. J., BAETSELIER, P. D., Michotte, Y. M., Muyldermans, S., et al. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01723.x · Cited by 62
Self-citationExploiting sequence and stability information for directing nanobody stability engineering
Kunz, P., Flock, T., Soler, N., Zaiß, M., Vincke, C., Sterckx, Y. G. ‐., Kastelic, D., Muyldermans, S., & Hoheisel, J. D. (2017) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2017.06.014 · Cited by 61
Development of Nanobodies Against Hemorrhagic and Myotoxic Components of Bothrops atrox Snake Venom
Bailón, H., Coronel, V. O. Y., Cáceres, O., Alave, E. G. C., Jhon, W., Rojas, C. P., Montejo, H., Neyra, D. G., Galarza, M., Bonilla, C., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00655 · Cited by 61
Interventions for cutaneous disease in systemic lupus erythematosus
Hannon, C. W., McCourt, C., Lima, H., Chen, S. C., & Bennett, C. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007478.pub2 · Cited by 58
Ruano‐Gallego, D., Fraile, S., Gutiérrez, C., & Fernández, L. Á. (2019) · Microbial Cell Factories · doi:10.1186/s12934-019-1094-0 · Cited by 58
Tu, Z., Chen, Q., Li, Y., Xiong, Y., Xu, Y., Hu, N., & Tao, Y. (2015) · Analytical Biochemistry · doi:10.1016/j.ab.2015.09.023 · Cited by 57
Kijanka, M. M., van Brussel, A. S. A., van der Wall, E., Mali, W. P. T. M., van Diest, P. J., Henegouwen, P. M. P. V. B. E., & Oliveira, S. (2016) · EJNMMI Research · doi:10.1186/s13550-016-0166-y · Cited by 57
Functionalization of gold nanoparticles with nanobodies through physical adsorption
Goossens, J., Sein, H., Lu, S., Radwanska, M., Muyldermans, S., Sterckx, Y. G. ‐., & Magez, S. (2017) · Analytical Methods · doi:10.1039/c7ay00854f · Cited by 54
Self-citationCampuzano, S., Salema, V. F., Moreno‐Guzmán, M., Gamella, M., Yáñez‐Sedeño, P., Fernández, L. Á., & Pingarrón, J. M. (2013) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2013.08.055 · Cited by 50
TNFR1 inhibition with a Nanobody protects against EAE development in mice
Steeland, S., Ryckeghem, S. V., Imschoot, G. V., Rycke, R. M. D., Toussaint, W., Vanhoutte, L., Vanhove, C., Vos, F. D., Vandenbroucke, R. E., & Libert, C. (2017) · Scientific Reports · doi:10.1038/s41598-017-13984-y · Cited by 50
Wang, Y., Li, X., Chen, X., Nielsen, J., Petranović, D., & Siewers, V. (2021) · Microbial Cell Factories · doi:10.1186/s12934-021-01624-0 · Cited by 47
Ta, D. T., Redeker, E. S., Billen, B., Reekmans, G., Sikulu, J., Noben, J., Guedens, W., & Adriaensens, P. (2015) · Protein Engineering Design and Selection · doi:10.1093/protein/gzv032 · Cited by 46
Rapid and Effective Generation of Nanobody Based CARs using PCR and Gibson Assembly
Munter, S. D., Parys, A. V., Bral, L., Ingels, J., Goetgeluk, G., Bonte, S., Pille, M., Billiet, L., Weening, K., Verhee, A., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030883 · Cited by 46
Zottel, A., Jovčevska, I., Šamec, N., Mlakar, J., Šribar, J., Križaj, I., Vidmar, M. S., & Komel, R. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920915302 · Cited by 45
Gelkop, S., Sobarzo, A., Brangel, P., Vincke, C., Romão, E., Fedida-Metula, S., Strom, N., Ataliba, I., Mwiine, F. N., Ochwo, S., et al. (2018) · Frontiers in Veterinary Science · doi:10.3389/fvets.2018.00250 · Cited by 44
Abderrazek, R. B., Vincke, C., Hmila, I., Saerens, D., Abidi, N., Ayeb, M. E., Muyldermans, S., & Bouhaouala‐Zahar, B. (2011) · Protein Engineering Design and Selection · doi:10.1093/protein/gzr037 · Cited by 41
Abbady, A. Q., Al-Daoude, A., Al-Mariri, A., Zarkawi, M., & Muyldermans, S. (2012) · Veterinary Immunology and Immunopathology · doi:10.1016/j.vetimm.2012.01.015 · Cited by 39
Odongo, S., Sterckx, Y. G. ‐., Stijlemans, B., Pillay, D., Baltz, T., Muyldermans, S., & Magez, S. (2016) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0004420 · Cited by 39
Self-citationEzzine, A., M’hirsi, S., Bouhaouala‐Zahar, B., Hmila, I., Baciou, L., & Marzouki, M. N. (2012) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.67 · Cited by 38
Camelid‐derived heavy‐chain nanobody against Clostridium botulinum neurotoxin E in Pichia pastoris
Baghban, R., Gargari, S. L. M., Rajabibazl, M., Nazarian, S., & Bakherad, H. (2014) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.1226 · Cited by 38
Maeda, R., Fujita, J., Konishi, Y., Kazuma, Y., Yamazaki, H., Anzai, I., Watanabe, T., Yamaguchi, K., Kasai, K., Nagata, K., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03630-3 · Cited by 38
Structural basis of VHH-mediated neutralization of the food-borne pathogen Listeria monocytogenes
King, M. T., Huh, I., Shenai, A., Brooks, T. M., & Brooks, C. L. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.003888 · Cited by 34
Salema, V. F., Mañas, C., Cerdán, L., Piñero‐Lambea, C., Marín, E., Roovers, R. C., Henegouwen, P. M. P. V. B. E., & Fernández, L. Á. (2016) · mAbs · doi:10.1080/19420862.2016.1216742 · Cited by 33
Chen, Q., Zhou, Y., Yu, J., Liu, W., Li, F., Xian, M., Nian, R., Song, H., & Feng, D. (2018) · Protein Expression and Purification · doi:10.1016/j.pep.2018.11.001 · Cited by 32
Keyaerts, M., Xavier, C., Everaert, H., Vaneycken, I., Fontaine, C., Decoster, L., Vanhoeij, M., Caveliers, V., & Lahoutte, T. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz095.081 · Cited by 31
Development of a nanobody-based immunoassay for the sensitive detection of fibrinogen-like protein 1
Zhang, W., Liu, T., Wu, M., Chen, X., Li, H., Shi, Z., Li, Y., Li, X.-Y., Xu, H., Gong, L., et al. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-00574-4 · Cited by 31
Diverse human VH antibody fragments with bio-therapeutic properties from the Crescendo Mouse
Teng, Y., Young, J. L., Edwards, B. M., Hayes, P., Thompson, L., Johnston, C. M., Edwards, C., Sanders, Y., Writer, M. J., Pinto, D., et al. (2019) · New Biotechnology · doi:10.1016/j.nbt.2019.10.003 · Cited by 30
Bernedo‐Navarro, R. A., Romão, E., Yano, T., Pinto, J., Greve, H. D., Sterckx, Y. G. ‐., & Muyldermans, S. (2018) · Toxins · doi:10.3390/toxins10030108 · Cited by 29
Glioblastoma-specific anti-TUFM nanobody for in-vitro immunoimaging and cancer stem cell targeting
Šamec, N., Jovčevska, I., Stojan, J., Zottel, A., Liović, M., Myers, M. P., Muyldermans, S., Šribar, J., Križaj, I., & Komel, R. (2018) · Oncotarget · doi:10.18632/oncotarget.24629 · Cited by 29
Gaiotto, T., Ramage, W., Ball, C., Risley, P., Carnell, G., Temperton, N. J., Engelhardt, O. G., & Hufton, S. E. (2021) · Scientific Reports · doi:10.1038/s41598-021-82356-4 · Cited by 29
Improving the yield of recalcitrant Nanobodies® by simple modifications to the standard protocol
Kariuki, C. K., & Magez, S. (2021) · Protein Expression and Purification · doi:10.1016/j.pep.2021.105906 · Cited by 29
Self-citationQin, X., Duan, M., Pei, D., Lin, J., Wang, L., Zhou, P., Yao, W., Guo, Y., Li, X., Lei, T., et al. (2021) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2021.07.003 · Cited by 27
In planta expression of nanobody-based designer chicken antibodies targeting Campylobacter
Vanmarsenille, C., Elseviers, J., Yvanoff, C., Hassanzadeh‐Ghassabeh, G., García, G. G.-J., Martens, E., Depicker, A., Martel, A., Haesebrouck, F., Pasmans, F., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0204222 · Cited by 25
Exploring single-domain antibody thermostability by molecular dynamics simulation
Mohseni, A., Molakarimi, M., Taghdir, M., Sajedi, R. H., & Hasannia, S. (2018) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2018.1526116 · Cited by 25
Inhibition of HIV replication through siRNA carried by CXCR4-targeted chimeric nanobody
Cunha-Santos, C., Perdigão, P. R. L., Martin, F., Oliveira, J. G., Cardoso, M. G., Manuel, A. M., Taveira, N., & Gonçalves, J. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03334-8 · Cited by 24
Nanobody production can be simplified by direct secretion from Escherichia coli
Iwaki, T., Hara, K., & Umemura, K. (2020) · Protein Expression and Purification · doi:10.1016/j.pep.2020.105607 · Cited by 23
Nanobody-Based Bispecific Neutralizer for Shiga Toxin-Producing E. coli
Lu, Z., Liu, Z., Li, X., Qin, X., Hong, H., Zhou, Z., Pieters, R. J., Shi, J., & Wu, Z. (2022) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.1c00456 · Cited by 23
Nanobodies against Pfs230 block Plasmodium falciparum transmission
Dietrich, M. H., Gabriela, M., Reaksudsan, K., et al. (2022) · Biochemical Journal · doi:10.1042/bcj20220554 · Cited by 23
Construction of Synthetic Nanobody Library in Mammalian Cells by dsDNA‐Based Strategies**
Zhao, Y., Wang, Y., Su, W., & Li, S. (2021) · ChemBioChem · doi:10.1002/cbic.202100286 · Cited by 21
Pinto, J., Odongo, S., Lee, F., Gaspariunaite, V., Muyldermans, S., Magez, S., & Sterckx, Y. G. ‐. (2017) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0005932 · Cited by 19
Self-citationLi, Z., Torres, J. E. P., Goossens, J., Vertommen, D., Caljon, G., Sterckx, Y. G. ‐., & Magez, S. (2020) · Vaccines · doi:10.3390/vaccines8030415 · Cited by 18
Self-citationAffinity Is an Important Determinant of the Anti-Trypanosome Activity of Nanobodies
Caljon, G., Stijlemans, B., Saerens, D., Abbeele, J. V. D., Muyldermans, S., Magez, S., & BAETSELIER, P. D. (2012) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0001902 · Cited by 17
Self-citationXu, L., Song, X., & Jia, L. (2017) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.1544 · Cited by 17
Let’s embrace optical imaging: a growing branch on the clinical molecular imaging tree
Noltes, M. E., van Dam, G. M., Nagengast, W. B., van der Zaag, P. J., Slart, R. H. J. A., Szymański, W., Kruijff, S., & Dierckx, R. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05476-z · Cited by 16
Hempelmann, A., Hartleb, L., van Straaten, M., Hashemi, H., Zeelen, J., Bongers, K., Papavasiliou, F. N., Engstler, M., Stebbins, C. E., & Jones, N. G. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109923 · Cited by 15
Sadeghian-Rizi, T., Behdani, M., Khanahmad, H., Hamid, M., & Jahanian‐Najafabadi, A. (2018) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527317666181114134518 · Cited by 14
Screening, Expression, and Identification of Nanobody against SARS-CoV-2 Spike Protein
Su, Q., Shi, W., Huang, X., Wan, Y., Li, G., Xing, B., Xu, Z. P., Liu, H., Hammock, B. D., Yang, X., et al. (2022) · Cells · doi:10.3390/cells11213355 · Cited by 13
Immobilization of Nanobodies with Vapor-Deposited Polymer Encapsulation for Robust Biosensors
Fan, R., Du, J., Park, K., Chang, L. H., Strieter, E. R., & Andrew, T. L. (2021) · ACS Applied Polymer Materials · doi:10.1021/acsapm.1c00140 · Cited by 10
Li, X., Liu, W., Li, H., Wang, X., & Zhao, Y. (2021) · Protein Expression and Purification · doi:10.1016/j.pep.2021.106030 · Cited by 7
Okello, E., Moonens, K., Erume, J., & Greve, H. D. (2021) · Agriculture · doi:10.3390/agriculture11030186 · Cited by 5
Correction: Affinity Is an Important Determinant of the Anti-Trypanosome Activity of Nanobodies
Caljon, G., Stijlemans, B., Saerens, D., Abbeele, J. V. D., Muyldermans, S., Magez, S., & BAETSELIER, P. D. (2012) · PLoS neglected tropical diseases · doi:10.1371/annotation/95386e26-78b2-44b1-af86-0028ba783156 · Cited by 3
Self-citation
Research works printed but not linked: 13
- Crauwels, 2020, Reshaping nanobodies for affinity purification on protein a, New Biotechnol., 57, 20, 10.1016/j.nbt.2020.01.005 · doi:10.1016/j.nbt.2020.01.005
- Li, 2019, Ribosome Display: A Potent Display Technology used for Selecting and Evolving Specific Binders with Desired Properties, Mol. Biotechnol., 61, 60, 10.1007/s12033-018-0133-0 · DOI
- Doerflinger, 2016, Development of a Nanobody-Based Lateral Flow Immunoassay for Detection of Human Norovirus, mSphere, 1, e00219-16, 10.1128/mSphere.00219-16 · doi:10.1128/msphere.00219-16
- Salvador, 2022, Nanobody-based lateral flow immunoassay for the rapid detection of aflatoxin B1 in almond milk, ACS Food Sci. Technol., 2, 1276, 10.1021/acsfoodscitech.2c00118 · DOI
- Zhang, 2021, Development of nanobody-based flow-through dot ELISA and lateral-flow immunoassay for rapid detection of 3-phenoxybenzoic acid, Anal. Methods Adv. Methods Appl., 13, 1757
- Yu, 2021, Generation of Dual functional Nanobody-Nanoluciferase Fusion and its potential in Bioluminescence Enzyme Immunoassay for trace Glypican-3 in Serum, Sens. Actuators. B Chem., 336, 129717, 10.1016/j.snb.2021.129717 · doi:10.1016/j.snb.2021.129717
- Li, 2020, An Ultrasensitive Bioluminescent Enzyme Immunoassay Based on Nanobody/Nanoluciferase Heptamer Fusion for the Detection of Tetrabromobisphenol A in Sediment, Anal. Chem., 92, 10083, 10.1021/acs.analchem.0c01908 · doi:10.1021/acs.analchem.0c01908
- Gu, 2022, Development of nanobody-horseradish peroxidase-based sandwich ELISA to detect Salmonella Enteritidis in milk and in vivo colonization in chicken, J. Nanobiotechnol., 20, 167, 10.1186/s12951-022-01376-y · doi:10.1186/s12951-022-01376-y
- Katz, 2021, Antigen sensing via nanobody-coated transistors, Nat. Biomed. Eng., 5, 639, 10.1038/s41551-021-00765-2 · doi:10.1038/s41551-021-00765-2
- Zheng, F., Luo, S., Ouyang, Z., Zhou, J., Mo, H., Schoonooghe, S., Muyldermans, S., De Baetselier, P., Raes, G., and Wen, Y. (2019). NIRF-Molecular Imaging with Synovial Macrophages-Targeting Vsig4 Nanobody for Disease Monitoring in a Mouse Model of Arthritis. Int. J. Mol. Sci., 20. · doi:10.3390/ijms20133347
- Hollifield, 2020, Caplacizumab: An anti-von Willebrand factor antibody for the treatment of thrombotic thrombocytopenic purpura, Am. J. Health-Syst. Pharm. AJHP Off. J. Am. Soc. Health-Syst. Pharm., 77, 1201, 10.1093/ajhp/zxaa151 · doi:10.1093/ajhp/zxaa151
- Ma, 2022, Preclinical development of a long-acting trivalent bispecific nanobody targeting IL-5 for the treatment of eosinophilic asthma, Respir. Res., 23, 316, 10.1186/s12931-022-02240-1 · doi:10.1186/s12931-022-02240-1
- Cunningham, 2021, RESPIRE study group Nebulised ALX-0171 for respiratory syncytial virus lower respiratory tract infection in hospitalised children: A double-blind, randomised, placebo-controlled, phase 2b trial, Lancet Respir. Med., 9, 21, 10.1016/S2213-2600(20)30320-9 · doi:10.1016/s2213-2600(20)30320-9
Cited by
Atomically accurate de novo design of antibodies with RFdiffusion
Bennett, N. R., Watson, J. L., Ragotte, R. J., Borst, A. J., See, D. L., Weidle, C., Biswas, R., Yu, Y., Shrock, E. L., Ault, R., et al. (2024) · doi:10.1101/2024.03.14.585103 · Cited by 324
Atomically accurate de novo design of antibodies with RFdiffusion
(2025) · doi:10.1038/s41586-025-09721-5 · Cited by 324
Current GMP standards for the large‐scale production of monoclonal antibodies
Troncoso‐Bravo, T., Pavez, V., Letelier, P., Del Río, J., Anabalón, C., Peñaloza, H. F., González, P. A., Bueno, S. M., & Kalergis, A. M. (2026) · Bioengineering & Translational Medicine · doi:10.1002/btm2.70121 · Cited by 2
Metadata
- Authors
- Jin, B.-K., Odongo, S., Radwanska, M., & Magez, S.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2023-03-22
- Volume
- 24
- Issue
- 6
- Pages
- 5994
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W4353090737
- Cited by
- 371
- References
- 146
- FWCI
- 54.76
- Type
- journal article
- Language
- en
- Open access
- gold
- Funders
- H2020-EU.3.2.1.1 Program COMBAT grant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.